Pyrotinib combined with apatinib for targeting metastatic non-small cell lung cancer with HER2 alterations: a prospective, open-label, single-arm phase 2 study (PATHER2)

Peer Review reports

Original Submission
11 Apr 2022	Submitted	Original manuscript
14 May 2022	Reviewed	Reviewer Report
17 May 2022	Reviewed	Reviewer Report
18 Jun 2022	Author responded	Author comments - Guangjian Yang
Resubmission - Version 2
18 Jun 2022	Submitted	Manuscript version 2
25 Jun 2022	Reviewed	Reviewer Report
1 Jul 2022	Reviewed	Reviewer Report
8 Jul 2022	Author responded	Author comments - Guangjian Yang
Resubmission - Version 3
8 Jul 2022	Submitted	Manuscript version 3
Publishing
8 Jul 2022	Editorially accepted
29 Aug 2022	Article published	10.1186/s12916-022-02470-6

Back to article page